Impetigo – Pipeline Review, H2 2019

“Global Markets Direct’s, ‘Impetigo – Pipeline Review, H2 2019’, provides an overview of the Impetigo pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Impetigo, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Impetigo and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.”

Scope


– The report provides a snapshot of the global therapeutic landscape of Impetigo

– The report reviews pipeline therapeutics for Impetigo by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Impetigo therapeutics and enlists all their major and minor projects

– The report assesses Impetigo therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Impetigo”

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Impetigo

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Impetigo pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

“Fujifilm Toyama Chemical Co Ltd

Laboratories Ojer Pharma SL

Lipidor AB

Next Science Ltd

SutroVax Inc

Union Therapeutics AS”

Table of Contents

Table of Contents

Table of Contents 2

Introduction 4

Impetigo Overview 5

Impetigo Therapeutics Development 6

Impetigo Therapeutics Assessment 12

Impetigo Companies Involved in Therapeutics Development 19

Impetigo Drug Profiles 21

Impetigo Dormant Projects 29

Impetigo Discontinued Products 30

Impetigo Product Development Milestones 31

Appendix 38

List of Tables

“List of Tables

Number of Products under Development for Impetigo, H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products under Development by Universities/Institutes, H2 2019

Products under Development by Companies, H2 2019

Products under Development by Universities/Institutes, H2 2019

Number of Products by Stage and Target, H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Impetigo – Pipeline by Fujifilm Toyama Chemical Co Ltd, H2 2019

Impetigo – Pipeline by Laboratories Ojer Pharma SL, H2 2019

Impetigo – Pipeline by Lipidor AB, H2 2019

Impetigo – Pipeline by Next Science Ltd, H2 2019

Impetigo – Pipeline by SutroVax Inc, H2 2019

Impetigo – Pipeline by Union Therapeutics AS, H2 2019

Impetigo – Dormant Projects, H2 2019

Impetigo – Discontinued Products, H2 2019”

List of Figures

“List of Figures

Number of Products under Development for Impetigo, H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products by Targets, H2 2019

Number of Products by Stage and Targets, H2 2019

Number of Products by Top 10 Mechanism of Actions, H2 2019

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019

Number of Products by Stage and Top 10 Routes of Administration, H2 2019

Number of Products by Molecule Types, H2 2019

Number of Products by Stage and Top 10 Molecule Types, H2 2019”

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports